Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Accured Expenses (2016 - 2025)

Ligand Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 34.92% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $5.9 million, down 57.69%, while the annual FY2025 figure was $5.9 million, 57.69% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $7.3 million at Ligand Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.3 million in Q4 2024 and bottomed at -$4.8 million in Q2 2021.
  • The 5-year median for Change in Accured Expenses is $31500.0 (2021), against an average of $727550.0.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 840.0% in 2021 before it plummeted 676.17% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $6.4 million in 2021, then plummeted by 145.54% to -$2.9 million in 2022, then soared by 193.94% to $2.8 million in 2023, then skyrocketed by 309.36% to $11.3 million in 2024, then tumbled by 34.92% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Accured Expenses are $7.3 million (Q4 2025), $1.1 million (Q3 2025), and -$407000.0 (Q2 2025).